Spleen stiffness measurement (SSM) offers a noninvasive method to diagnose portal hypertension in BCR::ABL1-negative MPN patients, potentially improving patient management. SSM captures hepatic ...
SAN DIEGO — Patients with cirrhosis treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant reductions in a range of portal hypertension complications and all-cause mortality ...
Charles D. Burger, MD: Portopulmonary hypertension is a subgroup of Group 1 pulmonary arterial hypertension [PAH], and it occurs in the setting of hepatic cirrhosis or end-stage liver disease. When ...
The suggested approach for the management of patients with compensated advanced chronic liver disease. Abbreviations: cACLD, compensated advanced chronic liver disease; CSPH, clinically significant ...
Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension (PH) being a primary driver of disease progression and ...
Thrombocytopenia in chronic liver disease arises from a variety of factors related to liver disease etiology, progression, and treatment. It is common in patients with cirrhosis and is a distinctive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results